RARE logo

Ultragenyx Pharmaceutical Inc. (RARE)

$16.70

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RARE

Market cap

$1.70B

EPS

-5.18

P/E ratio

--

Price to sales

2.13

Dividend yield

--

Beta

0.369677

Price on RARE

Previous close

$15.90

Today's open

$15.94

Day's range

$15.65 - $16.74

52 week range

$12.73 - $39.89

Profile about RARE

CEO

Emil D. Kakkis

Employees

1371

Headquarters

Novato, CA

Exchange

Nasdaq Global Select

Shares outstanding

101924068

Issue type

Common Stock

RARE industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RARE

Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches

Ultragenyx Pharmaceutical NASDAQ: RARE expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Biopharma Conference.

news source

MarketBeat • Nov 17, 2026

news preview

Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold

I initiate coverage of Ultragenyx Pharmaceutical with a Hold rating and $18 price target, citing a credible valuation floor but limited near-term catalysts. Two major late-stage pipeline failures have reset investor sentiment, and I see few meaningful catalysts over the next 12 months. RARE's legacy business is stable, but new gene therapies face payer pushback, tiny patient pools, and unproven durability, posing long-term risks.

news source

Seeking Alpha • Nov 12, 2026

news preview

Ultragenyx to Participate at Investor Conferences in London

NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences.

news source

GlobeNewsWire • Nov 11, 2026

news preview

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted on 28th October 2026 the Company's Marketing Authorisation Application (MAA) for rebisufligene etisparvovec (also known as rebi-vec or UX111), an investigational gene therapy for the treatment of mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A.

news source

GlobeNewsWire • Nov 6, 2026

news preview

Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock is trading lower on Wednesday after the company initiated substantial expense reductions to align expenses with revenue and achieve profitability by 2027.

news source

Benzinga • Nov 4, 2026

news preview

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Howard Horn - Executive VP of Corporate Strategy & CFO Erik Harris - Executive VP & Chief Commercial Officer Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Joon Lee Jaena Han - TD Cowen, Research Division Tazeen Ahmad - BofA Securities, Research Division Maxwell Skor - Morgan Stanley, Research Division Lydia Erdman - Goldman Sachs Group, Inc., Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.

news source

Seeking Alpha • Nov 4, 2026

news preview

Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot

Ultragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains highly concentrated in CRYSVITA, with new launches contributing minimally. Pipeline setbacks and terminated programs have forced a pivot from high-risk optionality to a leaner rare-disease commercial model.

news source

Seeking Alpha • Nov 4, 2026

news preview

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

Ultragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions intended to support GAAP profitability in 2027.

news source

MarketBeat • Nov 4, 2026

news preview

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million Substantial reduction of expenses and headcount underway, expected to drive at least a 50% reduction in 2027 R&D expenses vs 2025 NOVATO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profitability.

news source

GlobeNewsWire • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ultragenyx Pharmaceutical Inc.

Open an M1 investment account to buy and sell Ultragenyx Pharmaceutical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RARE on M1